[Post-genome challenges against inflammatory bowel diseases].
Advancement of genome analysis might give great impact to the treatment of inflammatory bowel diseases(IBD). IBD patients are treated by sulfadrugs, steroids and anti-immune drugs. For difficult cases, leukocytapheresis, beclomethasone dipropionate, anti-TNF therapy, anti-LTB4 therapy and other new methods are applied. Developing epoch-making drugs will be achieved by finding new molecular targets. Histologic identification of dysplasia is important in the surveillance of long-standing ulcerative colitis. The molecular diagnosis is required for the distinction of dysplasia from the regenerative inflammatory changes. P53 immunostaining have been proved useful. Various molecular targets will be taken into discussion as additional procedures. Recent genome analysis have revealed some genetic factors contribute to pathogenesis of IBD, which are HLA, IL4, MUC3, IBD1 locus, IBD2 locus and so on. More information about genes concerning IBD will be provided by analyzing dense SNP map using DNA tip. They will open the way to the tailored therapy.
Takei
Y
Y
Gunma Cancer Center.
Sawada
T
T
Sameshima
S
S
Nagasako
K
K
D015415:Biomarkers / Q000032:analysis; D015316:Genetic Therapy; D023281:Genomics; D016045:Human Genome Project; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D055263:Mucin-3; D009077:Mucins / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis; D020641:Polymorphism, Single Nucleotide; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics
D015415:Biomarkers; D055263:Mucin-3; D009077:Mucins; D016159:Tumor Suppressor Protein p53